-
1دورية أكاديمية
المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, CLEAR Trial Investigators
المساهمون: Gennigens, Christine
المصدر: New England Journal of Medicine, 384 (14), 1289 - 1300 (2021-04-08)
مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Quinolines, Everolimus, pembrolizumab, lenvatinib, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/mortality, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/mortality, Male, Middle Aged, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/therapeutic use, Quinolines/administration & dosage, Quinolines/adverse effects, Sunitinib/adverse effects, Sunitinib/therapeutic use, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms, Medicine (all), General Medicine, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie
العلاقة: http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716Test; urn:issn:0028-4793; urn:issn:1533-4406
الوصول الحر: https://orbi.uliege.be/handle/2268/300816Test
-
2
المؤلفون: Aida Oliván-Viguera, Minne Line Nedergaard Mikkelsen, Niels Marcussen, Olaf-Georg Issinger, Barbara Guerra, Maj Rabjerg, Ralf Köhler
المصدر: Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Scopus-Elsevier
Oncotarget
Rabjerg, M, Guerra, B, Oliván-Viguera, A, Mikkelsen, M L N, Köhler, R, Issinger, O G & Marcussen, N 2017, ' Nuclear localization of the CK2α-subunit correlates with poor prognosis in Clear Cell Renal Cell Carcinoma ', Oncotarget, vol. 8, no. 1, pp. 1613-1627 . https://doi.org/10.18632/oncotarget.13693Testمصطلحات موضوعية: RNA, Messenger/genetics, Male, 0301 basic medicine, Pathology, 0302 clinical medicine, Cell Movement, Renal cell carcinoma, Adenoma, Oxyphilic, Medicine, Nuclear protein, Casein Kinase II, Kidney Neoplasms/mortality, Aged, 80 and over, Middle Aged, Kidney Neoplasms, Carcinoma, Renal Cell/mortality, CK2-targeted therapy, Renal cancer, Oncology, 030220 oncology & carcinogenesis, Adenoma, Oxyphilic/mortality, CK2 subunits, Female, Biomarkers, Tumor/genetics, Casein kinase 2, Research Paper, Adult, medicine.medical_specialty, Naphthyridines/pharmacology, renal cancer, Cell Proliferation/genetics, 03 medical and health sciences, Cell Line, Tumor, Cell Movement/genetics, Biomarkers, Tumor, Humans, Neoplasm Invasiveness, Protein kinase CK2, RNA, Messenger, Naphthyridines, Kinase activity, Protein kinase A, Carcinoma, Renal Cell, Aged, Cell Proliferation, business.industry, Cell growth, CX-4945, Cancer, medicine.disease, Clear cell renal cell carcinoma, 030104 developmental biology, Casein Kinase II/antagonists & inhibitors, protein kinase CK2, Cancer research, Phenazines, Neoplasm Invasiveness/genetics, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15838774a213a8d184dcff9ff8745337Test
https://doi.org/10.18632/oncotarget.13693Test